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Abstract 
Human acute phase serum amyloid A (the A-SAA2 isoform) was expressed at high levels using the pGEX bacterial 
expression system. A-SAA2 protein was expressed in E. coli NM544 as part of a fusion protein facilitating rapid 
purification. A-SAA2 was cleaved from the fusion moiety in the presence of a non-ionic detergent (Triton X- 100) to release 
a soluble A-SAA2. Further purification using ion exchange chromatography yielded a pure A-SAA2 (3 mg per litre of 
culture). Antibodies generated against recombinant A-SAA2 were specific for the acute phase SAAs, A-SAA1 and A-SAA2 
and showed no cross-reactivity with the constitutively expressed SAA (C-SAA). These antibodies were used to develop a 
rapid enzyme-linked immunosorbent assay (ELISA) specific for the measurement of A-SAA in serum. 
Keynsords: Recombinant; Serum amyloid A protein; Acute phase protein; Amyloidosis; ELISA 
1. Introduction 
The mammalian acute phase response is the first 
line of systemic defence elicited by stimuli such as 
Abbreviations: SAA, serum amyloid A protein; A-SAA, acute 
phase SAA; C-SAA, constitutive SAA; APR. acute phase reac- 
tant: ELISA. enzvme-linked immunosorbent assav: HDL. high < - 
density lipoprotein; AA, amyloid A; GST, glutathione S-trans- 
ferase; IPTG, isopropyl P-Dthiogalactosidase; NIBSC, National 
Institute of Biological Standards and Controls; CRP. C-reactive 
protein; HRP, horseradish peroxidase. 
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infection, trauma, myocardial infarction, neoplasms, 
and surgery (Koj, 1985). It is initiated and main- 
tained by a large number of proinflammatory media- 
tors including cytokines, glucocorticosteroids and 
anaphylatoxins and involves a wide range of com- 
plex physiological changes including elevated circu- 
lating concentrations of hepatically synthesised acute 
phase reactants (APRs). In man, this latter class 
includes the ‘major’ APRs, serum amyloid A (SAA) 
and C-reactive protein (CRP) (reviewed by Steel and 
Whitehead, 1994). 
The human SAA gene family is comprised of four 
known genes that have been localised to the short 
arm of chromosome 11~15.1 (Sellar et al., 1994). 
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The SAA1 and SAA2 genes specify the two acute 
phase SAA (A-SAA) proteins A-SAA] and A-SAA2 
respectively which are both 104 amino acid. 12.5 
kDa proteins that share 93% amino acid sequence 
identity (Woo et al.. 1987; Betts et al., 1991). A 
number of allehc forms have been identified by 
amino acid sequence analysis of A-SAA isolated 
from plasma. The A-SAA] protein has three allelic 
forms whereas A-SAA2 has two (Dwulet et al., 
1988; Baba et al., 1993). A third gene SAA3 which 
shows 7 1% nucleotide identity with SAA1 and SAA2 
is a pseudogene (Kluve-Beckerman et al., 1991). 
Constitutive SAA (C-SAA) is the third expressed 
SAA family member (Whitehead et al.. 1992) and is 
the product of the SAAl gene (Steel et al.. 1993). 
C-SAA levels characteristically do not increase as a 
result of inflammation and exist in serum at concen- 
trations between SO-140 mg/l (Yamada et al.. 
1994a). C-SAA differs from A-SAA with respect to 
peptide length, being eight amino acids longer, and 
shares only 55% identity with A-SAAs. Addition- 
ally, C-SAA may be post-translationally modified by 
glycosylation at a single site (Whitehead et al., 1992). 
In common with the A-SAAs. C-SAA rapidly associ- 
ates with high density lipoprotein (HDL3) when 
released into the circulation (Eriksen and Benditt, 
1980; De Beer et al.. 1995). 
Circulating concentrations of A-SAA can increase 
up to 1000 mg/l within 24-48 h of an acute stimu- 
lus (Marhaug, 1983) indicating an important protec- 
tive role for these proteins: however, no definitive 
function has been demonstrated for the A-SAA pro- 
teins. Recent studies variously suggest that A-SAA 
has chemoattractant activity (Badolato et al., 1994). 
may play a role in lipid metabolism and immuno- 
suppression (Aldo-Benson and Benson. 1982; Guy- 
ton and Kemp, 1992) and may inhibit the oxidative 
burst in neutrophils (Linke et al., 1991). 
During chronic inflammation A-SAA levels re- 
main significantly elevated reflecting the continued 
persistence of underlying pathological inflammatory 
processes that can contribute to long term tissue 
damage. An occasional consequence of chronic in- 
flammation is reactive secondary amyloidosis (Pepys. 
19941, a progressive fatal condition in which amy- 
loid A protein (AA), a cleavage product of A-SAA, 
is the major component of insoluble fibrous deposits 
that accumulate in major organs (Husebekk et al., 
1985; Tape et al., 1988; Stone. 1990). The sustained 
elevation of A-SAA in chronic inflammatory condi- 
tions suggests that A-SAA is an important indicator 
of disease status. However. the measurement of A- 
SAA concentration has not been used for routine 
clinical diagnosis and clinical management, due in 
part to the difficulty in raising specific antisera 
against human A-SAA (Pepys, 1984). Several meth- 
ods including radioimmunoassays, single radial im- 
munodiffusion and ELISA based procedures have. 
however, been reported for the measurement of A- 
SAA levels (Chambers and Whither, 1983; Marhaug. 
1983; Taktak and Lee. 1991: Sipe et al., 1989: 
Yamada et al., 1989 and Casl and Grubb, 1993). As 
A-SAA in serum exists as one of the apolipoproteins 
associated with HDL3 particles many of these meth- 
ods require denaturation and delipidation of the serum 
samples prior to assay. 
Biological studies necessary to define clearly the 
role of A-SAA have been hampered due to problems 
encountered when working with the protein. Isola- 
tion of A-SAA from blood is laborious and results in 
poor yields of insoluble protein (Godenir et al.. 
1985; Strachan et al., 1989). Recombinant protein 
technology offers a means of generating a renewable 
homogeneous source of A-SAA. We report here the 
production of recombinant human A-SAA2 in E. 
coli as a GST fusion protein using the pGEX expres- 
sion system (Smith and Johnson, 1988). Expression 
of A-SAA2 in this system permits the recovery of 
soluble recombinant A-SAA2 protein following 
thrombin cleavage of the fusion protein when used in 
the presence of a mild non-ionic detergent. Antibod- 
ies raised against recombinant A-SAA2 were spe- 
cific for the A-SAAs and were used to develop a 
sandwich ELISA to quantify A-SAA levels in serum. 
2. Materials and methods 
2.1. Construction of the A-SAA2 protein expressim 
wctctr 
The coding region of A-SAA2 was amplified 
from the A-SAA2 cDNA clone by the polymerase 
chain reaction (PCR) with the concomitant introduc- 
tion of sequence specifying an additional glycine 
residue and a BarnHI restriction site at the 5’ end 
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(oligonucleotide primer sequence 5’-CGGGATCCG- 
GGCGAAGCTTCTTTTCGTTC-3’) and an EcoRI 
site at the 3’ end (oligonucleotide primer sequence 
5’-CGGAATTCAGTATTTCTCAGGCAGGCC-3’). 
The PCR product was digested with BumHI and 
EcoRI, gel purified, and ligated into the glutathione 
S-transferase (GST) fusion protein expression vector 
pGEX-2T (Pharmacia Fine Chemicals, Milton 
Keynes, UK). DNA sequence analysis of the result- 
ing pGEX-(A-SAA2) confirmed that it carried the 
entire unmodified A-SAA2 coding region positioned 
downstream of the GST coding region with no muta- 
tions resulting from the PCR process. 
2.2. Induction of E. coli cultures for high level 
expression of recombinant A-SAA2 protein 
Plasmid pGEX-(A-SAA2) was transformed into 
the E. cofi expression strain NM554. Transformants 
were isolated and grown overnight at 37°C. Overnight 
cultures were diluted 1 / 100 in Luria broth contain- 
ing 100 pg/ml ampicillin (Boehringer Mannheim, 
East Sussex, UK) and grown to an OD,, value of 
1.0. Expression of recombinant fusion protein was 
induced in culture with 0.1 mM isopropyl P-D- 
thiogalactosidase (IPTG: Sigma, Dorset, UK) for 5 h 
at 37°C. Cultures were centrifuged at 5000 X g for 
10 min at 4°C. Cell pellets were resuspended in 
l/50 of the starting volume in lysis buffer (PBS pH 
7.3 (Gibco/BRL, Paisley, UK) containing 0.2 
mg/ml lysozyme (Sigma); 5 mM EDTA (BDH, 
Merck, Dorset, England); 0.1% (v/v) Triton X-100 
(BDH); 50 mM benzamidine (Sigma); 0.1 mM PMSF 
(Sigma) and 0.5 mg m IO / 1 ’ d oacetamide (Sigma)) and 
incubated for 1 h at room temperature. Lysates were 
sonicated on ice (3 X 20 second bursts) to obtain 
complete lysis, centrifuged at 10000 X g for 10 min 
at 4°C and filtered through a 0.45 PM millipore 
filter to remove particulate material. Clarified soni- 
cates were passed through a Glutathione Sepharose 
4B column (Pharmacia) to which the GST-(A-SAA2) 
fusion protein bound. Contaminating E. coli proteins 
were removed by washing with ten column volumes 
of PBS (pH 7.3), and the recombinant A-SAA2 
protein was directly cleaved from the GST moiety on 
the glutathione Sepharose 4B column using thrombin 
(Sigma) (5 U/mg protein bound) in PBS (pH 7.3) 
0.1% (v/v) Triton X-100 at room temperature for 6 
h. The column eluate containing recombinant A- 
SAA2 was collected and stored at 4°C. The recombi- 
nant A-SAA2 sample was further purified by ion 
exchange chromatography using a column of high 
performance Sepharose Q (Pharmacia) equilibrated 
with 0.1% (v/v> Triton X- 100, 20 mM Tris-HCl (pH 
10.0) and eluted with 0.1% (v/v> Triton X-100, 20 
mM Tris-HCl (pH 10.01, 0.1 M NaCl. Fractions were 
collected and analysed by SDS-PAGE (Laemmli, 
1970; Sambrook et al., 1989) and immunoblotting 
(Towbin et al., 1979; Sambrook et al., 1989) using 
anticA-SAA) antiserum (see below) with 
peroxidase-conjugated goat anti-rabbit IgG (Sigma) 
as the secondary antibody. The protein content of the 
fractions was determined using Bicinchoninic Acid 
solution (Sigma) with crystalline bovine serum albu- 
min (Sigma) as standard. Recombinant A-SAA2 was 
stored at 4°C in buffer A (20 mM Tris-HCl (pH 8.4), 
150 mM NaCl and 0.1% (v/v> Triton X-100). 
2.3. N-terminal sequencing of recombinant A-SAA2 
Recombinant A-SAA2 was electroblotted onto a 
ProBlott membrane and stained with amido black 
prior to N-terminal amino acid sequencing on a 
Biosystems model 473A protein sequencer. 
2.4. Antibodies to A-SAA2 
Rabbits were immunised intramuscularly with re- 
combinant A-SAA2 purified from SDS-PAGE gels 
(Hager and Burgess, 1980) as follows: day 1, 1 ml of 
I mg/ml recombinant A-SAA2 in Freund’s com- 
plete adjuvant (Sigma); days 14 and 21, 1 ml of 1 
mg/ml recombinant A-SAA2 in Freund’s incom- 
plete adjuvant (Sigma). Blood was drawn on day 28. 
IgG-anticA-SAA) was isolated by affinity chro- 
matography on immobilised protein A (Pharmacia). 
2.5. 
2.6. A-SAA enzyme-linked inznzullosorbent u.ssrr~ 
(ELISA) 
Microtitre maxisorp plates (Nunc, Roskilde. Den- 
mark) were coated with 1 pg/ml protein A purified 
IgG-anti(A-SAA) in 0.1 M carbonate buffer (pH 9.6) 
overnight at 4°C. Plates were washed twice with 
PBST (PBS (pH 7.3), 0.05% (v/v) Tween 20) and 
stabilised using a BSA (Sigma) solution. The mi- 
crotitre plates were sealed and stored at 4°C until 
required. Recombinant A-SAA2 protein was used to 
generate standard curves. The standard curve range 
was 5-750 pg/l and was prepared in sample dilu- 
tion buffer (20 mM Tris-HCl (pH 7.8), 150 mM 
NaCl. 25% (v/v) propan-2-01). Serum samples to be 
analysed were diluted l/200 in sample dilution 
buffer and 100 ~1 of each dilution were added in 
duplicate to microwells. After incubation at room 
temperature (20-25°C) for 60 min with uniform 
shaking, wells were washed four times with 350 ~1 
PBST. Enzyme conjugate. IgG-anti(A-SAA)-HRP, 
was diluted l/800 in conjugate dilution buffer (50 
mM Tris-HCl (pH 7.8). 100 mM NaCl. I% (w/v) 
BSA) and 100 ~1 aliquots were added to the wells. 
Microtitre plates were incubated at room temperature 
(20-25°C) for a further 60 min with uniform shak- 
ing. The wells were again washed four times with 
350 ~1 PBST. 100 ~1 of stabilised tetramethylbenzi- 
dene (TMB: Moss, Pasadena, M.D, USA) substrate 
were added to each well using a multichannel pipette. 
and plates were incubated at room temperature for 
15 min. Colour development was stopped using 100 
~1 1 N H2S0, (BDH) and plates were read immedi- 
ately at OD,,, nm. The standard curve obtained 
using the recombinant A-SAA2 was used to calcu- 
late the A-SAA concentration in the test samples. In 
order to examine serum samples with low concentra- 
tions of A-SAA the conjugate was titred appropri- 
ately. 
2.7. Serum samples 
Normal serum samples were obtained from blood 
donors aged 18-65 years. Rheumatoid arthritis serum 
samples were obtained from patients undergoing rou- 
tine assessment in the Rheumatology Clinic of St 
James Hospital, Dublin. Samples were stored at 
-20°C prior to use. 
2.8. SAA stundud 
Recombinant A-SAA2 protein concentrations 
were determined using bicinchoninic acid solution 
(Sigma) with crystalline bovine serum albumin 
(Sigma) as standard. The recombinant A-SAA2 was 
diluted to a concentration of 150 mg/l and used as 
the A-SAA standard in the ELISA. 
2.9. Assuv Lalidutiorl 
The assay was validated by examining the follow- 
ing: linearity of dilution; reproducibility (intra- and 
interassay variation) and normal range determination. 
Experiments where recombinant A-SAA2 was added 
(spiked) into sample dilution buffer and into normal 
serum were conducted to examine the extent of 
masking of the A-SAA signal by serum. 
3. Results and discussion 
The A-SAAs constitute a major class of human 
acute phase reactant whose concentration can in- 
crease up to lOOO-fold following an acute inflamma- 
tory stimulus. No function for A-SAA has yet been 
definitively defined. While further studies are neces- 
sary to clearly define the role of A-SAA, problems 
obtaining a soluble purified native A-SAA have been 
encountered: purification of A-SAA protein from 
large volumes of blood is characterised by poor 
yields (Godenir et al.. 1985). limited solubility 
(Bausserman et al.. 1983) and the heterogeneous 
nature of the A-SAA recovered. In addition, A-SAA 
purified from serum may contain trace amounts of 
other serum components thereby potentially compro- 
mising studies of A-SAA function that involve sensi- 
tive bioassays. The production of A-SAA by recom- 
binant methods offers a reliable. homogeneous source 
of large quantities of highly purified A-SAA. We 
report the production of A-SAA2 using the pGEX 
bacterial expression system. The A-SAA2 coding 
region was inserted in frame into the pGEX-2T 
vector to produce a construct in which A-SAA2 
expression was under the control of the IPTG in- 
ducible tat promoter and GST ribosome binding 
site. Upon induction a 38.5 kDa GST-(A-SAA?) 
fusion protein was produced (Fig. 1, lane 4) consti- 
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Fig. 1. Q: expression of the recombinant A-SAA2 protein from 
pGEX(A-SAA21 analysed by SDS-PAGE. Lane 1: protein molec- 
ular weight markers 55.6, 39.2. 26.6, 12.5, 6.5 kDa; lane 2: 
pGEX(ASAA2) uninduced; lane 3: pGEX-2T expression vector 
induced with IPTG; lane 4: pGEX(ASAA2) induced with IPTG; 
lane 5: thrombin cleaved mature A-SAA2 product; lane 6: purified 
recombinant A-SAA2 following ion-exchange chromatography. b: 
solubility of recombinant GST-(A-SAA21 fusion protein. Recom- 
binant GST-(A-SAAZ) fusion protein was tested for solubility in 
the presence and absence of nonionic detergent 0.1% (v/v) Triton 
X-100. SDS-PAGE analysis: lane 1: protein molecular weight 
markers 55.6, 39.2, 26.6, 12.5 kDa; lane 2: insoluble fraction after 
cell lysis without the presence of 0.1% (v/v) Triton X-100; lane 
3: soluble fraction without the presence of 0.1% (v/v) Triton 
X-100; lane 4: insoluble fraction after cell lysis in the presence of 
0.1% (v/v) Triton X-100; lane 5: soluble fraction in presence of 
0.1% (v/v) Triton X-100. 
was cleaved by thrombin in the presence of 0.1% 
(v/v) Triton X-100 to yield a soluble A-SAA2 
product of 12.5 kDa (the predicted size for mature 
A-SAA2) (Fig. 1, lane 5). Further purification of 
recombinant A-SAA2 was achieved using ion ex- 
change chromatography and the resulting protein 
could be resolved as a single band on SDS-PAGE 
(Fig. 1, lane 6). N-terminal amino acid sequence of 
the 12.5 kDa product was Gly-Ser-Gly-Arg-Ser-Phe- 
Phe-Ser-(Phe/Asp/Ala)-Leu-Gly-(Glu/Asp)-Ala- 
Phe-Asp-Gly-Ala-Arg-Asp, confirming its identity as 
A-SAA2 with an amino terminal Gly-Ser-Gly exten- 
sion derived from the fusion protein. Approximately 
3 mg of recombinant A-SAA2 was obtained per litre 
of bacterial culture. 
Previously reported methods for producing re- 
combinant A-SAA2 require the presence of strong 
chaotropic agents such as urea and guanidine hydro- 
chloride to achieve maximum soluble protein recov- 
ery (Kluve-Beckerman et al., 1993; Yamada et al., 
1994b). The use of such harsh denaturing agents 
renders the task of isolating active protein more 
difficult (Marino, 1989; Schein, 1989). As no clear 
biological function has been established for A-SAA 
it is impossible to determine whether the use of such 
strong denaturing agents compromises or abolishes 
A-SAA protein activity. Nonionic detergents are less 
likely to disrupt protein-protein interactions as these 
detergents have an uncharged head group and have 
been shown to be particularly useful for isolating 
functional proteins (Scopes, 1982). 
Recombinant A-SAA2 was used to raise antibod- 
ies in rabbits. The resulting antiserum was tested for 
cross reactivity with other human SAA protein fam- 
ily members and serum components by immunoblot 
analysis (Fig. 2). It reacted with (i) purified recombi- 
nant A-SAA2 (Fig. 2, lane 1); (ii) A-SAA (but no 
1234 567 
tuting approximately 5% of the total cellular protein. 
Solubilisation of GST-(A-SAA2) from lysed E. coli 
cell pellets requires the presence of 0.1% (v/v> 
Triton X-100 (Fig. lb). Following capture of the 
fusion protein on GST Sepharose 4@, the protein 
Fig. 2. Specificity of anti(ASAA2) antibodies. Immunoblot analy- 
sis using antiserum raised against recombinant A-SAA2. Lane 1: 
recombinant A-SAA2; lane 2: serum of an acute phase patient: 
lane 3: non-acute phase serum; lane 4: NIBSC A-SAA; lane 5: 
recombinant C-SAA; lane 6: recombinant A-SAAl; lane 7: re- 
combinant A-SAA2 spiked into non-acute phase serum. 
other molecular species) present in the serum of a 
patient with inflammation (Fig. 2. lane 2) and A-SAA 
obtained from the NIBSC (Fig. 2, lane 41; (iii) 
recombinant A-SAA2 spiked into non-acute phase 
serum (Fig. 2, lane 71; and (iv) recombinant A-SAA 1 
(expressed and purified as for A-SAA2; unpub- 
lished) (Fig. 2, lane 6). Antibodies raised against 
recombinant A-SAA2 generate equivalent signals 
with both recombinant A-SAA1 and recombinant 
A-SAA2 in the immunoblot (Fig. 2, compare lanes I 
and 6) indicating that the binding capacity for each 
isofoim is essentially equivalent. In addition, the 
antibodies raised against recombinant A-SAA2 do 
not cross react with purified C-SAA (expressed and 
purified as for A-SAA’, unpublished) (Fig. 2, lane 
51 or any component of non-acute phase serum (Fig. 
2, lane 3). 
There is considerable interest in measuring A-SAA 
concentrations in serum as sustained high levels of 
circulating A-SAA may constitute an important as- 
pect in the pathogenesis of some inflammation asso- 
ciated conditions (e.g. secondary amyloidosisl and 
may be an accurate marker for other pathogenic 
factors in a number of diseases with an inflammatory 
component (Husebekk et al., 1986; Mozes et al.. 
1989; Maury et al., 1988; Muller et al., 1992; Liuzzo 
et al., 1994). We used the polyclonal antibodies 
raised against recombinant A-SAA2 to develop a 
simple and rapid sandwich ELISA for measuring 
A-SAA levels in serum. Some of the previously 
reported A-SAA immunoassays used SAA isolated 
from acute phase serum to generate antibodies 
(Marhaug. 1983; Sipe et al.. 1989: Wilkins et al.. 
1994). As C-SAA is present in both normal and 
acute phase serum, antibodies raised against SAA 
isolated from acute phase serum may exhibit cross- 
reactivity with C-SAA and pre-absorption of anti- 
bodies with normal serum is required to eliminate 
this cross-reactivity (Wilkins et al., 19941. The 
anti&SAA) antiserum reported here was raised 
against recombinant A-SAAZ, is specific for A-SAA. 
and requires no additional absorption steps prior to 
use. 
Some previous reports of methods to measure 
A-SAA in patient serum have identified problems 
associated with quenching of the A-SAA signal by 
serum components (Casl and Grubb, 1993). To ad- 
dress this issue, we conducted experiments in which 
Table I 
Masking experiments: spiking of recombinant A-SAA2 into non- 
xxte phase serum 
(a) Spiking of recombinant A-SAA2 into non-acute phase serum 
Dilution buffer 
Recombinant A-SAA2 Recombinant A-SAA2 % recovery 
kg/l spiked pg/l recovered 
750 190 26 
375 120 32 
IXX 40 21 
Serial dilutions were carried out in dilution buffer without 25% 
(i 1’~ ) propan-2-01. 
(b) Spiking of recombinant A-SAA2 into non-acute phase serum 
Dilution buffer with 25% (v/v) propan-2-01) 
Recombinant A-SAA2 Recombinant A-SAA2 c/c’ recovery 
pg/I spiked pg/l recovered 
750 740 98 
375 358 95 
IX8 I78 95 
Serial dilutions were carried out in dilution buffer with 25% (v/v) 
propan-2-01. 
purified recombinant A-SAA2 was added to serum 
(spiked) and interference caused by serum compo- 
nents was quantified. Recombinant A-SAA2 at a 
known concentration was spiked into (i) buffer A 
and (ii) non-acute phase serum, and assayed using 
the sample dilution buffer without 25% (v/v) 
propan-2-01. Only 26% recovery of signal was ob- 
served following the spiking of recombinant A-SAA2 
into non-acute phase serum (Table la>. The above 
spiking experiment was repeated using sample dilu- 
tion buffer containing 25% (v/v> propan-2-01. In the 
presence of the organic solvent almost complete 
recovery of signal was observed following spiking of 
recombinant A-SAA2 into non-acute phase serum 
(Table 1 b). The propan-2-01 sample dilution buffer 
most likely achieves signal recovery by disrupting 
the hydrophobic apolipoprotein complexes thereby 
facilitating antibody access to otherwise hidden A- 
SAA epitopes. It has been reported that SAA puri- 
fied from acute phase serum exhibits a different 
immunoreactive dilution profile from that of purified 
SAA reconstituted back into normal serum (Godenir 
et al.. 1985; Yamada et al., 1989). From our studies 
purified recombinant A-SAA2 in buffer A. A-SAA2 
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spiked into non-acute phase serum, and native A- 
SAA in serum from a rheumatoid arthritis patient, all 
show similar serial dilution profiles when diluted in 
our sample dilution buffer (Fig. 3). The presence of 
propan-2-01 in the sample dilution buffer offers a 
simple, rapid alternative to previous methods (delipi- 
dation and denaturation) used to unmask the A-SAA 
in serum samples (Marhaug, 1983; Chambers and 
Whither, 1983; Casl and Grubb, 1993). 
In the A-SAA sandwich ELISA serum samples 
were routinely run at l/200 dilution. The lower and 
upper limits of the low range standard curve were 5 
1*.8/i and 100 pg/l respectively. The lower and 
upper limits of the high range standard curve were 
50 pg/l and 750 pg/l, respectively (Fig. 4) and 
samples falling above this range were diluted appro- 
priately so that their A-SAA levels fell within the 
range of the curve. For assay validation the linearity 
0.5 - 
0 I 
10 100 1000 
A-SAA concentration ug/L 
Fig. 4. Standard curve for A-SAA. The standard curve (50-750 








l/100 l/ZOO l/400 l/800 l/1600 113200 l/6400 
Serial dilution 
Fig. 3. Serial dilution profile. Native A-SAA (A). recombinant A-SAA2 spiked into normal serum (B) and recombinant A-SAA2 (0 were 
serially diluted in buffer A using sample dilution buffer containing 25% (v/v) propan-2-01. Dilution profile for recombinant A-SAA2 spiked 
into normal serum (D) and recombinant A-SAA2 in buffer A (El using dilution buffer without 25% (v/v) propan-2-01. 
108 
Patient Number 
Fig. 5. Measurement of A-SAA concentration in the xrum of rheumatoid arthritis patienta. 
of sample dilution was analysed by carrying out 
serial dilutions and the resulting data show that assay 
parallelism is observed in the ELBA. The repro- 
ducibility of the ELISA method was analysed by 
intra-assay and interassay variability. The intra-assay 
coefficient of variation from 20 replicate assays of 
three A-SAA serum samples (A-SAA concentrations 
were 5. 130 and 244 mg/l) were 4.8, 5.0 and 6.7Yc. 
respectively. The interassay coefficient of variation 
in ten replicate assays on the same serum samples 
were 8.0, 6.2 and 6.0%. respectively. 
The normal range for A-SAA was analysed using 
50 serum samples from healthy individuals. and 
determined to be 0.4 mg/l ) 0.57 mg/l using the 
standard equation: mean f 2 SD. The A-SAA con- 
centrations in 30 serum samples from rheumatoid 
arthritis patients undergoing routine assessment in 
the Rheumatology Department. St James Hospital, 
Dublin were analysed using the ELISA procedure 
and 95% of rheumatoid arthritis patients showed an 
elevated level of A-SAA (Fig. 51. 
A-SAA proteins are difficult to isolate, purify and 
solubilise. The production of A-SAA2 by thrombin 
cleavage from a GST-(A-SAA2) fusion protein in 
conjunction with the use of triton X-100 for solubili- 
sation offers a means of generating large amounts of 
homogeneous A-SAA. As the recovery of soluble 
A-SAA2 by this method is possible without the use 
of harsh denaturants the resulting material may be 
particularly suited to future studies of A-SAA struc- 
ture and biological function. Antibodies generated 
against recombinant A-SAA2 were shown to be spe- 
cific for A-SAAs and used to develop an ELBA for 
quantifying A-SAA in patient serum. Monitoring 
acute phase protein levels is of considerable clinical 
importance in the assessment of inflammatory dis- 
ease activity and response to therapy and the ELISA 
reported here provides a simple, rapid and repro- 
ducible method for such monitoring. 
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